VP-16-213. A phase II trial using a weekly schedule.
Forty-six patients with various malignancies refractory to standard chemotherapy were treated with VP-16-213 using a weekly schedule. Only one patient responded to this regimen. perivenous infiltration of VP-16-213 resulted in a soft-tissue ulceration; this side effect has not been reported before. We conclude that VP-16-213 is of little utility when used in a weekly fashion in previously treated patients.
D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*
D005047:Etoposide; D011034:Podophyllotoxin